BridgeBio Enters into Clinical Collaboration with BMS to Evaluate BBP-398 + Opdivo for Advanced Solid Tumors with KRAS Mutations
Shots:
- The companies will initiate P-I/II study evaluating the safety and preliminary efficacy of BBP-398 in combination with both Opdivo as dual therapy & Opdivo + KRASG12C inhibitor as triplet therapy in NSCLC patients with KRAS mutations- as 1L & 2L treatment options
- BridgeBio will sponsor the study while BMS will provide nivolumab to the study. Both the companies will share the cost of clinical development activities for the combination study
- BridgeBio is currently advancing its P-I trial in patients with solid tumors driven by mutations in the MAPK signaling pathway- including RAS and receptor tyrosine kinase genes
Ref: BridgeBio | Image: BMS
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com